(Q44373513)

2 December 2017

title

Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines (English)

1 reference

2 December 2017

7

Rademaker M

1 reference

2 December 2017

Litjens NH

1

1 reference

2 December 2017

Nibbering PH

2

1 reference

2 December 2017

Barrois AJ

3

1 reference

2 December 2017

Zomerdijk TP

4

1 reference

2 December 2017

Van Den Oudenrijn AC

5

1 reference

2 December 2017

Noz KC

6

1 reference

2 December 2017

Van De Meide PH

8

1 reference

2 December 2017

Van Dissel JT

9

1 reference

2 December 2017

Thio B

10

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

British Journal of Dermatology

2 December 2017

published in

1 reference

2 December 2017

volume

148

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

444-451

1 reference

Which T cells cause psoriasis?

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

1,25-Dihydroxyvitamin D3--a hormone with immunomodulatory properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

[Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients].

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

Inhibition of dendritic cell differentiation by fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

Psoriasis of early and late onset: A clinical and epidemiologic study from Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2003.05153.X

10.1046/J.1365-2133.2003.05153.X

21 January 2018

Identifiers

DOI

1 reference

release_m5q36rfevva5fnsm3uds5mqmfm

2 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m5q36rfevva5fnsm3uds5mqmfm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference